SCHEDULE: Millennium Entities Disclose 5.5% Stake in Karyopharm
Beneficial Ownership Disclosure
Millennium Management LLC and affiliated entities have reported a collective beneficial ownership of 5.5% in Karyopharm Therapeutics Inc. common stock.
Summary
- Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G regarding their beneficial ownership in Karyopharm Therapeutics Inc.
- Integrated Core Strategies (US) LLC beneficially owns 997,577 shares, representing 5.4% of the class.
- Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 1,008,662 shares, representing 5.5% of the class.
- The reporting persons share both voting and dispositive power over their respective reported shares.
- The securities were not acquired for the purpose of changing or influencing the control of Karyopharm Therapeutics Inc.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive development, indicating significant institutional interest in Karyopharm Therapeutics Inc. by Millennium Management and its affiliates.
Positives
- Significant institutional ownership by Millennium Management and its affiliates could signal investor confidence in Karyopharm Therapeutics Inc.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Karyopharm Therapeutics Inc.'s future performance or operations.
Industry Context
StockSavvy.ai notes that significant institutional ownership by prominent investment firms like Millennium Management can often be interpreted by the market as a vote of confidence in a company's long-term prospects, particularly within the biotechnology sector where Karyopharm Therapeutics operates. Such disclosures can attract further investor attention to the stock.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Joint Filing Agreement | Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander entered into a Joint Filing Agreement to file the Schedule 13G jointly. | 02/09/2026 | This agreement streamlines the reporting process for the affiliated entities and clarifies their collective beneficial ownership. |
Stakeholder Impact
- Shareholders of Karyopharm Therapeutics Inc. will observe increased institutional ownership, which may influence market perception, trading volume, and potentially the stock's stability.
Key Dates
| Date | Description |
|---|---|
| 02/04/2026 | Date of event which requires filing of this statement |
| 02/09/2026 | Date of signing and filing of the Schedule 13G and Joint Filing Agreement |
Keywords
Karyopharm Therapeutics, KPTI, Millennium Management, Integrated Core Strategies, Israel A. Englander, Schedule 13G, beneficial ownership, institutional investment, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.